Low molecular weight versus standard heparin for prevention of venous thromboembolism after major abdominal surgery

The Lancet

Volumn 341, Issue 8840, 1993, Pages 259-265

  Kakkar, V V ^a   Cohen, A T ^a   Edmonson, R A ^a   Phillips, M J ^a   Das, S K ^a   Maher, K T ^a   Sanderson, R M ^a   Kakkar, S ^a   Cooper, D J ^b  

^a THROMBOSIS RESEARCH INSTITUTE   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DALTEPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ABDOMINAL SURGERY; ADULT; AGED; ARTICLE; BLEEDING; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROPHYLAXIS; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOEMBOLISM; THROMBOSIS;

ABDOMEN; ADULT; AGED; CHI-SQUARE DISTRIBUTION; COMPARATIVE STUDY; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HEMORRHAGE; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMAN; MALE; MIDDLE AGE; POSTOPERATIVE COMPLICATIONS; RISK FACTORS; SUPPORT, NON-U.S. GOV'T; THROMBOEMBOLISM;

EID: 0027455778     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/0140-6736(93)92614-Y     Document Type: Article

References (33)

1. Low molecular weight heparin in the prophylaxis of venous thrombosis
2. Efficcy and safety of low-molecular-weight heparin (CY 216) in preventing postoperative venous thromboembolism: a co-operative study
3. Efficacy and safety of two regimens of low molecular weight heparin fragment (Fragmin) in preventing postoperative venous thromboembolism
4. Comparison of a low molecular weight heparin and unfractionated heparin for the prevention of deep vein thrombosis in patients undergoing abdominal surgery
5. Prevention of perioperative deep vein thrombosis in general surgery: a multicentre double-blind study comparing two doses of logiparin and standard heparin
6. Low molecular weight heparin (Kabi 2165) as thromboprophylaxis in elective visceral surgery: a randomised, double-blind study versus unfractionated heparin
7. Low molecular weight heparin plus dihydroergotamine for prophylaxis of postoperative deep vein thrombosis
8. A new low molecular weight heparin for deep vein thrombosis prevention: effectiveness in postoperative patients
9. A prospective randomized trial of low molecular weight heparin-DHE and conventional heparin-DHE (with Acenocoumarol) in patients undergoing gynaecological surgery
10. Fixed combinations of low-molecular weight or unfractionated heparin plus dihydroergotamine in the prevention of postoperative deep vein thrombosis
11. The antithrombotic activity and pharmacokinetics of Enoxaparin a low molecular weight heparin in man given single subcutaneous doses of 20 up to 80 mg
12. Unfractionated heparin and CY216. Pharmacokinetics and bioavailabilities of the anti-factor Xa and IIa: effects of intravenous and subcutaneous injection in rabbits
13. Low molecular weight heparin (KABI 2165, fragmin): pharmacokinetics after intravenous and subcutaneous administration in human volunteers
14. Pharmacokinetics of low molecular weight heparins
15. Kinetics of intravenously administered heparin in normal humans
16. The relationship between the haemorrhagic and antithrombotic properties of low molecular weight heparins and heparin
17. Comparison between commercial heparin, low molecular weight heparin and pentosan polysulphate on haemostasis and platelets in vivo
18. Postoperative pulmonary embolism after hospital discharge: an underestimated risk
19. The natural history of postoperative venous thromboemboli in gynaecological oncology: a prospective study of 382 patients
20. Prevention of fatal postoperative pulmonary embolism by low doses of heparin an international multicentre trial
21. Binding of heparin and low molecular weight heparin fragments to human vascular endothelial cells in culture
22. Neutralizaton of heparin-related saccharides by histidine-rich glycoprotein and platelet factor 4
23. Heparin inhibition of von Willebrand factor-dependent platelet function in vitro and in vivo
24. The efficacy and safety of low molecular weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis
25. Pharmacotherapeutic aspects of unfractionated and low molecular weight heparins
26. The kinetics of haemostatic enzyme—antithrombin interactions in the presence of low molecular weight heparin
27. A low molecular weight heparinoid anticoagulant with a long half-life in man
28. Binding and endocytosis of heparin by human endothelial cells in culture
29. Prophylaxis of venous thrombo-embolism: analysis of cost effectiveness
30. The economics of general thromboembolic prophylaxis